hi OHDSI - i wanted to bring to your attention our pre-print:
I am very new to observational health data, and OHDSI,
several members of OHDSI have been kind enough to provide us with some guidance,
including @msuchard @aki-nishimura.
our study protocol continues to improve, to bring it up to OHDSI standards.
as it stands, our retrospective analysis has been sufficient to:
- lead to johns hopkins (#1 hospital in the world) start a clinical inpatient trial using alpha blockers, the first trial approved at JHH
- get FDA approval to run a multi-center trial
BUT, we don’t have any evidence from COVID patients yet,
and we have a study that could be improved and scaled by this community even in pneumonia and acute respiratory success.
we have been fortunate enough to raise money to support these efforts,
so we are now actively looking for partners in both the COVID data analysis plan/implementation,
and the actual clinical trial partnerships.
we are also talking with a number of other funders, pharma, etc., and getting more support/encouragement as existing potential remedies seem to be falling.
If anybody is interested, please let me know.
many thanks for all your guidance, openness, and leadership throughout this crisis.